Boston Scientific Q1 beat: sales $3.39B (+14% organic), adj EPS $0.47, guides up

BOSTON SCIENTIFIC CORP

2023-Q1 EPS reported $0.21 revenue$3,389,000,000

Q1 net sales $3.389B (+14% organic vs guide 6-8%), GAAP EPS $0.21, adjusted EPS $0.47 vs guide $0.42-0.44.
Cardiovascular +15.9% operational; MedSurg +13.4%; U.S. +12.7%, EMEA +20% operational.
FY23 organic sales growth guidance raised to 8-10%; adjusted EPS forecast $1.90-$1.96.
Q2 guidance: organic sales +7-9%; adjusted EPS $0.48-$0.50.
Closed acquisitions of Apollo Endosurgery and majority stake in Acotec; FDA clearance for LithoVue Elite.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BOSTON SCIENTIFIC CORP reported first quarter ended March 31, 2023 results: revenue $3.389 billion, net income $300 million or $0.21 per share (EPS), compared to $97 million or $0.07 per share a year ago, and achieved adjusted EPS, EPS $0.21 per share.

Period: first quarter ended March 31, 2023
Revenue: $3.389 billion
Net income: $300 million or $0.21 per share (EPS), compared to $97 million or $0.07 per share a year ago, and achieved adjusted EPS
EPS: $0.21 per share
Result: reported results

Exact text from the filing

RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2023 Marlborough, Mass. (April 26, 2023) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational 1 basis and 14.0 percent on an organic 2 basis, all compared to the

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-23-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.